Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Prodrugs

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeted Degradation of Capsid by Host-Hijacking PROTAC Overcomes Drug Resistance.

Journal of medicinal chemistry·2026

Same author

Electrochemical Cobalt-Catalyzed Difunctionalization of Alkenes and Alkynes: Recent Advances in Synthetic Applications.

Chemical record (New York, N.Y.)·2026

Same author

Synergistic cesium carbonate-promoted dehydration of ketonitrones: stereoselective synthesis of indenyl-2-azadienes.

Chemical communications (Cambridge, England)·2026

Same author

Visible-Light-Driven Reductive 1,2-Diarylation of Alkenes via <i>O</i>-Tethered Iodoarenes and Cyanopyridines.

The Journal of organic chemistry·2026

Same author

Pyridoimidazolyl Sulfonamide Compound <b>2</b>: A Superior Dual-Acting Drug Candidate with Potent URAT1 Inhibition and Anti-Inflammatory Activity for Gout Management.

Journal of medicinal chemistry·2026

Same author

Bridging the Gap between <i>In Vitro</i> and Intracellular: Systematic Analysis and Screening Optimization of Inconsistencies between Target Activity and Cellular-Level Activity.

Journal of medicinal chemistry·2026

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Exploring Privileged Structure Repurposing: Target Similarity as a Catalyst for Cross-Species Drug Discovery.

Shaoqing Du¹, Kai Tang², Jinheng Li¹

¹College of Chemical Engineering, State Key Laboratory of Advanced Optical Polymer and Manufacturing Technology, Qingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, Qingdao University of Science and Technology, Qingdao 266061, Shandong, P. R. China.

Journal of Medicinal Chemistry

|July 7, 2026

Summary

This study presents a strategy for drug repositioning using privileged drug structures and homologous protein targets. It details computational methods and medicinal chemistry techniques to optimize lead compounds for improved drug development efficiency.

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Related Experiment Videos

Last Updated: Jul 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Area of Science:

Medicinal Chemistry
Computational Biology
Drug Discovery

Background:

Privileged drug structures possess inherent drug-like properties, crucial for therapeutic development.
Cross-species drug repositioning requires prioritizing targets based on conserved homologous proteins within virus families.
Identifying safe, druggable privileged structures is essential for successful drug repurposing.

Purpose of the Study:

To outline a systematic strategy for cross-species drug repositioning utilizing privileged drug structures.
To detail the application of computational and structural biology methods for target-based drug optimization.
To highlight key medicinal chemistry strategies for lead compound enhancement.

Main Methods:

Prioritization of viral targets based on protein homology and functional conservation.
Identification and validation of safe and druggable privileged drug structures.
Application of computational chemistry and structural biology for binding affinity and interaction analysis.
Optimization of lead compounds using side-chain replacement, conformational constraint, and scaffold hopping.

Main Results:

Demonstration of a validated strategy through representative case studies.
Identification of challenges including off-target toxicity and scaffold modification difficulties.
Potential for improved drug development efficiency and responsiveness to clinical needs.

Conclusions:

The proposed strategy leverages privileged structures and computational methods to enhance drug repositioning.
Medicinal chemistry interventions are key to optimizing lead compounds for novel therapeutic applications.
Addressing practical challenges is vital for realizing the full potential of this drug development approach.